Diamyd(R) Diabetes Vaccine Receives Approval To Start Phase III Trials In Europe

Diamyd Medical
(OMX: DIAM B)(OTC: DMYDY)announced that the Swedish Medical Products
Agency (MPA) has approved the Company's application to commence Phase III
studies with the therapeutic diabetes vaccine Diamyd(R).


"I am extremely glad that we now can offer our recently diagnosed type
1 diabetes patients the possibility to participate also in the European
study," says Professor Johnny Ludvigsson, Linkoping, Sweden, Principal
Investigator for the study.



Diabetes teams from approximately 20 Swedish pediatric clinics will
meet in Linkoping, Sweden on April 4 to go through details for the study,
which will comprise 306 new onset type 1 diabetes patients. Diamyd Medical
is planning to file clinical trial applications in another 3-4 European
countries and include additionally 20 clinics in the study.



"The approval from the Swedish MPA is another important step in the
development of Diamyd(R) towards the market," says Elisabeth Lindner,
President and CEO of Diamyd Medical. "Last week we received authorization
from the FDA to start a parallel Phase III trial in the US, and together
with TrialNet's planned study in the US, the interest in Diamyd is strong.
We receive daily inquiries from parents of patients wanting to participate
in our studies."



Disclaimer: This document contains certain statements relating to the
progress, timing and completion of our research, development and clinical
trials. These statements can be affected by inaccurate assumptions or by
known or unknown risks and uncertainties. Diamyd Medical undertakes no
obligation to publicly update such statements, whether because of new
information, future events or otherwise, nor does Diamyd Medical give any
guarantees that the statements, given or implied, are correct. This
document is a translation from the Swedish original. No guarantees are made
that the translation is free from errors.


Diamyd Medical AB

diamyd